Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 18 of 29

Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With Statins

In patients with hyperlipidemia and decreased eGFR or creatinine clearance, statins reduced the risk for mortality, myocardial infarction, and stroke versus a control. Mortality was reduced by 20 percent (ARR = 1.6%, 7.1% vs. 8.7%; RR 0.80, 95% CI, 0.68–0.95; 8 trials, n = 13,964; high strength of evidence); the risk for myocardial infarction was reduced by 28 percent (ARR = 2.6%; 6.8% vs. 9.4%; RR = 0.72, 95% CI 0.54–0.98; 2 trials, n = 2,015 patients); and the risk for stroke was reduced by 38 percent (ARR = 0.9%; 1.4% vs. 2.3%; RR = 0.62, 95% CI 0.41–0.95; 6 trials, n = 10,369 patients). No statin trials reported clinical outcomes data for patients with albuminuria. In patients with CKD, there is low-level evidence that there is no difference in risk of mortality between treatment with a high-dose versus low-dose statin.

Abbreviations:
95% CI = 95-percent confidence interval; ARR = absolute risk reduction; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; RR = risk ratio